What is Gilead Sciences Inc (GILD)?
Gilead Sciences Inc is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. The company specializes in antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, among other viral infections. Gilead's portfolio includes therapies for oncology, inflammatory diseases, and cardiovascular conditions, reflecting its commitment to addressing unmet medical needs. The company operates globally, with research facilities and commercial operations spanning multiple countries. Gilead invests significantly in scientific research and clinical development to advance its pipeline of therapeutic candidates. Its approach integrates cutting-edge science with strategic partnerships and acquisitions to enhance its product offerings. The company also emphasizes access to medicines and collaborates with healthcare providers and organizations worldwide to improve patient outcomes. Gilead Sciences Inc is recognized for its contributions to antiviral therapy and continues to play a prominent role in the pharmaceutical industry through ongoing innovation and development.
Gilead Sciences Inc Stock Price Today: Live Overview
The price today is shaped by ongoing market fluctuations, as Gilead Sciences Inc trades at $141.80. It has ranged between $139.95 and $141.98, reflecting a daily change of -0.7014%.
FAQ: Gilead Sciences Inc (GILD)
What is the current price of GILD stock?
Gilead Sciences Inc's stock price is $141.80.
Does GILD pay dividends?
Gilead Sciences Inc pays dividends via cash distributions (if applicable).
Does GILD have a formal corporate presence or regional headquarters in the UAE?
Gilead Sciences Inc operates in the UAE via partners and distributors without a direct office.
What is GILD best known for?
Gilead Sciences Inc is most famous for its antiviral drugs and therapies.
What assets are typically shown together with GILD?
Commonly shown alongside GILD: Cytokinetics Inc, Seres Therapeutics Inc, Lenz Therapeutics Inc
Latest shares articles



